Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Valeant Pharmaceuticals unveils new executive

Valeant Pharmaceuticals unveils new executive

8th January 2009

Valeant Pharmaceuticals (VP) has announced the appointment of a new chief operating officer of specialty pharmaceuticals.

Rajiv De Silva, a former employee of Novartis, was revealed this week as the company’s choice for future operations involving the overseeing of all pharmaceutical decisions in its US, Canadian and Australian markets.

Mr De Silva’s most recent position at his former employer was as president of Novartis Vaccines USA and head of Vaccines for the Americas – roles which he held since 2007, having joined the firm four years earlier.

Commenting on the announcement, VP’s chairman and chief executive officer J Michael Pearson said it was hoped this level of experience would equip Mr De Silva for his new responsibilities.

“His experience in the global pharmaceutical industry and his track record on the operations side should serve as important assets to the Valeant team as we continue to focus our business on efficiency and profitability,” he added.

The new chief operating officer of specialty pharmaceuticals assumes his position from January 5th and has expressed his excitement at joining a company which he states could have a great future.

It was announced last week that VP had completed the acquisition of Dow Pharmaceutical Sciences.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.